Genetic alterations are a major driver of NRF2 dysregulation in cancer, particularly mutations in KEAP1, NFE2L2 (NRF2), and CUL3, which disrupt KEAP1-mediated ubiquitination and lead to constitutive NRF2 stabilization [27,28]. Here, NFE2L2 is linked to cancer.